Background & aim: Translational models are essential to identify improved treatment options for chronic kidney disease (CKD) patients. However, most preclinical CKD models do not demonstrate reduced glomerular filtration rate (GFR) or improvement by standard of care (SoC). The aim…
Background & aim: Bulk RNA-sequencing has limited cellular-level insight into metabolic-associated steatohepatitis (MASH) and its progression to hepatocellular carcinoma (HCC) by masking rare and tumor-relevant populations. Here, we used single-cell transcriptomics to characterize liver cell-specific transcriptomic changes in the GAN…
Background & aim: Growing evidence suggests that senescent cells contribute to the development and progression of idiopathic pulmonary fibrosis (IPF). The present study aimed to evaluate molecular signatures of pulmonary senescence in the single and repetitive bleomycin (BLEO)-induced and spirometry-confirmed…
Abstract: Nintedanib, a multitargeted tyrosine kinase inhibitor, is approved for idiopathic pulmonary fibrosis (IPF) for its ability to slow lung function decline. This study systematically evaluated the effects of nintedanib across three independent treatment intervention studies in the single-dose bleomycin…
Background & aim: The current understanding of diabetic kidney disease (DKD) has significant gaps regarding the underlying pathogenesis. In this study, we aimed to characterize the temporal progression of DKD using a state-of-the-art mouse model of hypertension-accelerated disease, integrating kidney…
Background & aim: Obesity, hyperglycemia and hypertension are critical risk factors for development of diabetic kidney disease (DKD). While emerging evidence suggests that glucagon-like peptide-1 receptor (GLP1R) agonists improve cardiovascular and renal outcomes in type 2 diabetes patients, their mode…
Background & aim: NLT-101 is a first-in-class compound that functions by proximity engagement with a target in the nuclear envelope that mediates its activity. NLT-101 is in preclinical development for metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis driven indications. The present…
Background & aim: A detailed mapping of functional differences among intestinal regions in healthy individuals remains incomplete. Identifying regional alterations in individuals with type 2 diabetes (T2D) could enhance our understanding of disease-related intestinal changes. Aim: To characterise the transcriptomic…
